课题基金 / 基金详情

Cerebrovascular diseases and Brain Ageing – a program of research into novel mechanisms, risk prevention and innovative health care delivery

Cerebrovascular diseases and Brain Ageing – a program of research into novel mechanisms, risk prevention and innovative health care delivery
脑血管疾病和脑衰老——新机制、风险预防和创新医疗保健服务的研究计划
批准号:
nhmrc : 1061457
负责人:
Prof Velandai Srikanth
金额:
$31.11万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Career Development Fellowships
财政年份:
2014
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2014-01-01 至 2017-12-31

项目摘要

项目成果

Prof Velandai Srikanth的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This research is aimed at understanding the ways in which age-related vascular disease affecting the brain leads to walking difficulty, cognitive impairment and falls in older people. It is also designed to discover potentially modifiable risk factors for such vascular disease. Ultimately the goal of this research is to design and conduct trials of interventions aimed at slowing the process of vascular brain ageing.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Brain Ageing - studying causes and developing interventions
  • 批准号:
    nhmrc : GNT1137837
  • 项目类别:
    Practitioner Fellowships
  • 资助金额:
    $48.12万
  • 财政年份:
    2018
  • 负责人:
    Prof Velandai Srikanth
  • 依托单位:
Brain Ageing - studying causes and developing interventions
  • 批准号:
    nhmrc : 1137837
  • 项目类别:
    Practitioner Fellowships
  • 资助金额:
    $32.53万
  • 财政年份:
    2018
  • 负责人:
    Prof Velandai Srikanth
  • 依托单位:
Cerebrovascular diseases and Brain Ageing
  • 批准号:
    nhmrc : GNT1061457
  • 项目类别:
    Career Development Fellowships
  • 资助金额:
    $44.78万
  • 财政年份:
    2014
  • 负责人:
    Prof Velandai Srikanth
  • 依托单位:
Cerebrovascular Disease and Dementia in Ageing Populations
  • 批准号:
    nhmrc : 606544
  • 项目类别:
    Career Development Fellowships
  • 资助金额:
    $26.3万
  • 财政年份:
    2010
  • 负责人:
    Prof Velandai Srikanth
  • 依托单位:
国内基金
海外基金
cGAS-STING通路调控单核细胞活化参与Graves病发病的机制研究
  • 批准号:
    82370787
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    王曙
  • 依托单位:
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis